Literature DB >> 30635277

Exosomes from Nischarin-Expressing Cells Reduce Breast Cancer Cell Motility and Tumor Growth.

Mazvita Maziveyi1, Shengli Dong1, Somesh Baranwal2, Ali Mehrnezhad3, Rajamani Rathinam4, Thomas M Huckaba5, Donald E Mercante6, Kidong Park3, Suresh K Alahari7.   

Abstract

Exosomes are small extracellular microvesicles that are secreted by cells when intracellular multivesicular bodies fuse with the plasma membrane. We have previously demonstrated that Nischarin inhibits focal adhesion formation, cell migration, and invasion, leading to reduced activation of focal adhesion kinase. In this study, we propose that the tumor suppressor Nischarin regulates the release of exosomes. When cocultured on exosomes from Nischarin-positive cells, breast cancer cells exhibited reduced survival, migration, adhesion, and spreading. The same cocultures formed xenograft tumors of significantly reduced volume following injection into mice. Exosomes secreted by Nischarin-expressing tumors inhibited tumor growth. Expression of only one allele of Nischarin increased secretion of exosomes, and Rab14 activity modulated exosome secretions and cell growth. Taken together, this study reveals a novel role for Nischarin in preventing cancer cell motility, which contributes to our understanding of exosome biology. SIGNIFICANCE: Regulation of Nischarin-mediated exosome secretion by Rab14 seems to play an important role in controlling tumor growth and migration.See related commentary by McAndrews and Kalluri, p. 2099. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30635277      PMCID: PMC7204893          DOI: 10.1158/0008-5472.CAN-18-0842

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK.

Authors:  Suresh K Alahari
Journal:  Exp Cell Res       Date:  2003-08-15       Impact factor: 3.905

2.  Structure-Function Analyses of the Interactions between Rab11 and Rab14 Small GTPases with Their Shared Effector Rab Coupling Protein (RCP).

Authors:  Patrick Lall; Andrew J Lindsay; Sara Hanscom; Tea Kecman; Elizabeth S Taglauer; Una M McVeigh; Edward Franklin; Mary W McCaffrey; Amir R Khan
Journal:  J Biol Chem       Date:  2015-05-31       Impact factor: 5.157

Review 3.  Breast Cancer Tumor Suppressors: A Special Emphasis on Novel Protein Nischarin.

Authors:  Mazvita Maziveyi; Suresh K Alahari
Journal:  Cancer Res       Date:  2015-09-21       Impact factor: 12.701

4.  Molecular characterization of the tumor-suppressive function of nischarin in breast cancer.

Authors:  Somesh Baranwal; Yanfang Wang; Rajamani Rathinam; Jason Lee; Lianjin Jin; Robin McGoey; Yuliya Pylayeva; Filippo Giancotti; Gerard C Blobe; Suresh K Alahari
Journal:  J Natl Cancer Inst       Date:  2011-09-14       Impact factor: 13.506

5.  Rac and Rab GTPases dual effector Nischarin regulates vesicle maturation to facilitate survival of intracellular bacteria.

Authors:  Coenraad Kuijl; Manohar Pilli; Suresh K Alahari; Hans Janssen; Poh-Sim Khoo; Karen E Ervin; Monica Calero; Sobhanaditya Jonnalagadda; Richard H Scheller; Jacques Neefjes; Jagath R Junutula
Journal:  EMBO J       Date:  2013-02-05       Impact factor: 11.598

6.  Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer.

Authors:  Young Kyung Bae; Aeri Kim; Min Kyoung Kim; Jung Eun Choi; Su Hwan Kang; Soo Jung Lee
Journal:  Hum Pathol       Date:  2013-05-14       Impact factor: 3.466

Review 7.  The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.

Authors:  John P Alao
Journal:  Mol Cancer       Date:  2007-04-02       Impact factor: 27.401

Review 8.  Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications.

Authors:  Silvia Juliana Serrano-Gomez; Mazvita Maziveyi; Suresh K Alahari
Journal:  Mol Cancer       Date:  2016-02-24       Impact factor: 27.401

9.  Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation.

Authors:  Patricia Carrasco-Ramírez; David W Greening; Germán Andrés; Shashi K Gopal; Ester Martín-Villar; Jaime Renart; Richard J Simpson; Miguel Quintanilla
Journal:  Oncotarget       Date:  2016-03-29

10.  Dynamic modeling of cell migration and spreading behaviors on fibronectin coated planar substrates and micropatterned geometries.

Authors:  Min-Cheol Kim; Devin M Neal; Roger D Kamm; H Harry Asada
Journal:  PLoS Comput Biol       Date:  2013-02-28       Impact factor: 4.475

View more
  12 in total

Review 1.  Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance.

Authors:  Hassan Yousefi; Mousa Vatanmakanian; Mojdeh Mahdiannasser; Ladan Mashouri; Nikhilesh V Alahari; Mohammad Rafiee Monjezi; Shahrzad Ilbeigi; Suresh K Alahari
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

Review 2.  Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance.

Authors:  Hassan Yousefi; Maryam Maheronnaghsh; Fatemeh Molaei; Ladan Mashouri; Amir Reza Aref; Majid Momeny; Suresh K Alahari
Journal:  Oncogene       Date:  2019-10-10       Impact factor: 9.867

Review 3.  Emerging role of exosomes in cancer progression and tumor microenvironment remodeling.

Authors:  Mahshid Deldar Abad Paskeh; Maliheh Entezari; Sepideh Mirzaei; Amirhossein Zabolian; Hossein Saleki; Mohamad Javad Naghdi; Sina Sabet; Mohammad Amin Khoshbakht; Mehrdad Hashemi; Kiavash Hushmandi; Gautam Sethi; Ali Zarrabi; Alan Prem Kumar; Shing Cheng Tan; Marios Papadakis; Athanasios Alexiou; Md Asiful Islam; Ebrahim Mostafavi; Milad Ashrafizadeh
Journal:  J Hematol Oncol       Date:  2022-06-28       Impact factor: 23.168

4.  Circulating Serum Exosomal Long Non-Coding RNAs FOXD2-AS1, NRIR, and XLOC_009459 as Diagnostic Biomarkers for Colorectal Cancer.

Authors:  Miao Yu; Xing-Guo Song; Ya-Jing Zhao; Xiao-Han Dong; Li-Min Niu; Zhi-Jun Zhang; Xiao-Ling Shang; You-Yong Tang; Xian-Rang Song; Li Xie
Journal:  Front Oncol       Date:  2021-03-12       Impact factor: 6.244

5.  [MicroRNA-671-3p suppresses proliferation and invasion of breast cancer cells by targeting DEPTOR].

Authors:  Wei Xia; Degui Gong; Xiaoping Qin; Zhuo Cai
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

Review 6.  Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer.

Authors:  Samuel C Okpechi; Hassan Yousefi; Khoa Nguyen; Thomas Cheng; Nikhilesh V Alahari; Bridgette Collins-Burow; Matthew E Burow; Suresh K Alahari
Journal:  Oncogene       Date:  2022-01-22       Impact factor: 9.867

7.  Profilin 2 promotes growth, metastasis, and angiogenesis of small cell lung cancer through cancer-derived exosomes.

Authors:  Qi Cao; Yihan Liu; Ying Wu; Caijiao Hu; Lei Sun; Jinghui Wang; Changlong Li; Meng Guo; Xin Liu; Jianyi Lv; Xueyun Huo; Junming Yue; Xiaoyan Du; Zhenwen Chen
Journal:  Aging (Albany NY)       Date:  2020-11-21       Impact factor: 5.682

8.  Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens.

Authors:  Romain Darrigrand; Alison Pierson; Marine Rouillon; Dolor Renko; Mathilde Boulpicante; David Bouyssié; Emmanuelle Mouton-Barbosa; Julien Marcoux; Camille Garcia; Michael Ghosh; Mouad Alami; Sébastien Apcher
Journal:  Commun Biol       Date:  2021-03-01

Review 9.  Extracellular vesicles: emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy.

Authors:  Manling Wu; Min Wang; Haoyuan Jia; Peipei Wu
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 10.  Ubiquitination-Dependent Regulation of Small GTPases in Membrane Trafficking: From Cell Biology to Human Diseases.

Authors:  Zehui Lei; Jing Wang; Lingqiang Zhang; Cui Hua Liu
Journal:  Front Cell Dev Biol       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.